AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki clinical trials

A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.

This study is testing a new tablet, AP1189, for people recently diagnosed with rheumatoid arthritis who haven't tried other strong medicines yet. It aims to see how well different doses of AP1189 lower inflammation and improve symptoms when taken with another common arthritis medicine.